Author Archives: admin

Parkinsons Disease Treatment Market 2020 Global Industry Analysis, by Key Players, Segmentation, Application, Demand and Forecast by 2025 – Science…

By adminJanuary 31, 2020Gene Therapy Clinics

Global Parkinsons Disease Treatment Market 2020-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of Parkinsons Disease Treatment Market at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Get Discount:https://www.adroitmarketresearch.com/contacts/discount/615

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report athttps://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

What can hold back the hands of time? Scientists have looked at these five treatments – Ottawa Citizen

By adminJanuary 31, 2020Gene Therapy Clinics

Scientists have been researching ways to increase a humans healthspan and possible lifespan for decades. Here are things they have considered, and what they have learned.

The intervention:Rapamycin

What is it? First identified in the 1970s in a soil sample from Easter Island, this FDA-approved drug is used to suppress the immune system in transplant patients. Counterintuitively, it also appears to boost immune function in healthy animals. Rapamycin may reduce inflammation, which increases with age. One study found that rapamycin rejuvenated the hearts of old mice. After treatment, there were significant improvements to cardiac function. Research with mice has also found that even when they where administered rapamycin late in life, the mice still had improvements to lifespan and their healthspan.

The verdict: Geroscientist Matt Kaeberlein said rapamycin shows the most promise of any drug that targets aging, in his opinion, although he doesnt necessarily think rapamycin will increase lifespan by 20 to 30 years on average in people. Although it might at the right dose. I do think theres reason to believe that rapamycin could improve several age-related health problems, including boosting immune function and protecting against dementia, cancers, and heart disease.

But critics say it is unclear what the downstream effects could be. If you take a compound like that for a few decades, there may be downstream effect a small epidemic of lymphoma, perhaps, said geriatrician Dr. Peter Boling. While it is approved to prevent rejection in organ transplant patients, it is not approved to treat aging.

There are also questions about side effects, which may include susceptibility to infection and the possibility of developing lymphoma.

We still dont know about all of the hidden dangers. As hopeful as we might be, we have to be aware of the limitations, said Boling.

The intervention: Metformin

What is it? This drug has been prescribed to millions of people to treat diabetes. Among other effects, it decreases insulin levels. It also appears to target biological mechanisms related to aging. Its anti-aging effects may be linked to its influences on metabolic and cellular processes associated with inflammation. It has been linked to lifespan extension and protection against age-related diseases in animal models.

The verdict: The speculation in scientific circles has been that many of the drugs used to treat early-stage chronic disease may be effective, at least in part, because they target aging itself.

Metformin is an interesting case, said Kaeberlein. It clearly increases survival in people with diabetes and likely would do the same for pre-diabetics and others with significant metabolic disease, which represents a growing percentage of adults, he said. However, its less clear whether metformin will be beneficial in people who are metabolically healthy and exercise regularly.

The studies in mice suggest that metformin is different from rapamycin, in the sense that metformin only increases lifespan by a very small amount and in some cases has been reported to have no effect or even shortens lifespan in mice.

The FDA has accepted a clinical trial, Targeting Aging with Metformin, known as TAME, which will test whether metformin can delay the onset of age-related diseases and conditions including cancer, cardiovascular disease and Alzheimers disease. The goal of the trial, which is estimated to cost $55 million, is not to help people live to be 120 years old but to add health to our years, said the American Federation for Aging Research.

Like metformin, several promising drugs show great potential and await trials. If successful, the TAME trial would give the pharmaceutical industry impetus to advance these drugs and transform aging from a period of sickness to a time of extended vitality.

The intervention: Caloric restriction

What is it? A dietary regimen that reduces calories while maintaining nutrients. Research in lab animals, which started almost a century ago, has shown that it is possible to delay age-related diseases in mice and rats through dietary and caloric restriction, but results have varied.

A parallel study of two groups of rhesus monkeys, one at the University of Wisconsin and the other at the U.S. National Institute on Aging, looked at the life-prolonging and health effects of a calorie-restricted diet. The researchers found that the Wisconsin monkeys on a diet with 30 per cent fewer calories than the control group survived to about 28 years for males and about 30 years for females a couple of years above average for monkeys in captivity. Calorie-restricted monkeys in both groups showed fewer age-related health conditions compared to the control monkeys.

Some biohackers people who use biological interventions to optimize health have embarked on caloric restriction diets, with the goal of living longer. Entrepreneur Dave Asprey, author of Bulletproof Diet, has said he plans to live to be 180 and is hacking his own biology with a number of interventions, including supplements and a strict diet.

The verdict so far: The rhesus monkey study also produced some contradictory findings. The National Institute on Agings study found that while the dieting monkeys showed improved health, they didnt necessarily live longer than the control monkeys. Its not clear why there was a difference between the two groups of monkeys, although they were fed different diets and had different feeding times and access to food. The ages at which they dieted may also have come into play.

There is no compelling evidence caloric restriction will work with people, said Doug Gray, a molecular biologist with an interest in the role of protein homeostasis in aging and diseases of aging at the Ottawa Hospital Research Institute.

If this sounds like a depressing route to extreme longevity, even scientists agree. Noted one researcher: Life might seem longer, but it wouldnt necessarily be longer.

The intervention: Gene editing

What is it? Genome editing, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced.

Last February, for example, the journal Nature Medicine reported on a therapy using CRISPR-Cas9 genome editing technology aimed at suppressing rapid aging in mice with the rare genetic disorder progeria, which causes accelerated aging. According to the report, two months after the therapy, the progeria mice were stronger and more active and had better heart health. Their lifespan also increased by about 25 per cent.

The verdict so far: Not ready for prime time, said Boling. Even though we have successfully mapped the human genome, and its technically possible to remove a gene sequence and replace it, we have yet to successfully edit genes in a complex organism. Many people dont want to eat food containing genetically-modified organisms, let alone become one, he said.

I dont think we have a clear handle on a special gene sequence that would essentially change the aging process. I would want to see if we could do it in a limited and focused way without undue downstream consequences.

The intervention: Young blood

What is it? There have been a number of studies that looked at whether giving old mice blood from young mice could reverse some signs of aging. Even the researchers admitted it sounded creepy, but the results were intriguing. One study at the University of California, Berkeley, published in 2018, found that old mice showed benefits, including better muscle repair, from receiving blood from young mice. But young mice who received old blood had negative effects, including performing poorly on a strength test.

In 2017, researchers at Stanford University medical school reported that injections of blood plasma from donors between the ages of 18 and 30 showed promise for helping human Alzheimers patients with mild to moderate symptoms regain some ability to perform basic daily tasks, such as remembering to take their medications or preparing meals. The results were based on reports from the patients and their caregivers. The researchers cautioned that more research is needed, since the trial involved only nine patients who had received plasma infusions and nine who had received a placebo saline infusion.

The verdict so far: Dont try it. In a statement last February, the FDA said it had significant public health concerns about establishments that offer infusions of plasma from young donors to treat conditions ranging from normal aging and memory loss to Parkinsons disease, multiple sclerosis, Alzheimers disease, and PTSD.

Simply put, were concerned that some patients are being preyed upon by unscrupulous actors touting treatments of plasma from young donors as cures and remedies. Such treatments have no proven clinical benefits for the uses for which these clinics are advertising them and are potentially harmful, warned the FDA. There are reports of bad actors charging thousands of dollars for infusions that are unproven and not guided by evidence from adequate and well-controlled trials.

Read the original here:
What can hold back the hands of time? Scientists have looked at these five treatments - Ottawa Citizen

Snake venom can now be made in a lab and that could save many lives – KTVZ

By adminJanuary 29, 2020Stem Cell Doctors

If youre unlucky enough to have a poisonous snake sink its fangs into you, your best hope is an antivenom, which has been made in the same way since Victorian times.

It involves milking snake venom by hand and injecting it into horses or other animals in small doses to evoke an immune response. The animals blood is drawn and purified to obtain antibodies that act against the venom.

Producing antivenom in this way can get messy, not to mention dangerous. The process is error prone, laborious and the finished serum can result in serious side effects.

Experts have long called for better ways to treat snake bites, which kill some 200 people a day.

Now finally scientists are applying stem cell research and genome mapping to this long-ignored field of research. They hope it will bring antivenom production into the 21st Century and ultimately save thousands, if not hundreds of thousands, of lives each year.

Researchers in the Netherlands have created venom-producing glands from the Cape Coral Snake and eight other snake species in the lab, using stem cells. The toxins produced by the miniature 3-D replicas of snake glands are all but identical to the snakes venom, the team announced Thursday.

In a parallel breakthrough, scientists in India have sequenced the genome of the Indian cobra, one of the countrys big four snakes that are responsible for most of the 50,000 snakebite deaths India sees a year.

Theyve really moved the game on, said Nick Cammack, head of the snakebite team at UK medical research charity Wellcome. These are massive developments because its bringing 2020 science into a field thats been neglected.

Hans Clevers, the principal investigator at the Hubrecht Institute for Developmental Biology and Stem Cell Research in Utrecht, never expected to be using his lab to make snake venom.

A decade ago, he invented the technique to make human organoids miniature organs made from the stem cells of individual patients. Theyve allowed doctors to test the specific effects of drugs safely outside the body, something that has revolutionized and personalized areas such as cancer treatment.

So why did he decide to culture a snake venom gland?

Clevers said it was essentially a whim of three PhD students working in his lab whod grown bored of reproducing mouse and human kidneys, livers and guts. I think they sat down and asked themselves what is the most iconic animal we can culture? Not human or mouse. They said its got to be the snake. The snake venom gland.

They assumed that snakes would have stem cells the same way mice and humans have stems cells but nobody had ever investigated this, said Clevers.

After sourcing some fertilized snake eggs from a dealer, the researchers found they were able to take a tiny chunk of snake tissue, containing stem cells, and nurture it in a dish with the same growth factor they used for human organoids albeit at a lower temperature to create the venom glands. And they found that these snake organoids tiny balls just one millimeter wide produced the same toxins as the snake venom.

Open them up and you have a lot of venom. As far as we can tell, its identical. Weve compared it directly to the venom from the same species of snake and we find the exact same components, said Clevers, who was an author of the paper that published in the journal Cell last week.

The team compared their lab-made venom with the real thing at the genetic level and in terms of function, finding that muscle cells stopped firing when exposed to their synthetic venom.

The current antivenoms available to us, produced in horses not humans, trigger relatively high rates of adverse reactions, which can be mild, like rash and itch, or more serious, like anaphylaxis. Its also expensive stuff. Wellcome estimate that one vial of antivenom costs $160, and a full course usually requires multiple vials.

Even if the people who need it can afford it most snakebite victims live in rural Asia and Africa the world has less than half of the antivenom stock it needs, according to Wellcome. Plus antivenoms have been developed for only around 60% of the worlds venomous snakes.

In this context, the new research could have far-reaching consequences, allowing scientists to create a biobank of snake gland organoids from the 600 or so venomous snake species that could be used to produce limitless amounts of snake venom in a lab, said Clevers.

The next step is to take all that knowledge and start investigating new antivenoms that take a more molecular approach, said Clevers.

To create an antivenom, genetic information and organoid technology could be used to make the specific venom components that cause the most harm and from them produce monoclonal antibodies, which mimic the bodys immune system, to fight the venom, a method already used in immunotherapy treatments for cancer and other diseases.

Its a great new way to work with venom in terms of developing new treatments and developing antivenom. Snakes are very difficult to look after, Cammack said, who was not involved with the research.

Clevers said his lab now plans to make venom gland organoids from the worlds 50 most venomous animals and they will share this biobank with researchers worldwide. At the moment, Clevers said they are able to produce the organoids at a rate of one a week.

But producing antivenom is not an area that pharmaceutical companies have traditionally been keen to invest in, Clevers said

Campaigners often describe snakebites as a hidden health crisis, with snakebites killing more people than prostrate cancer and cholera worldwide, Cammack said.

Theres no money in the countries that suffer. Dont underestimate how many people die. Sharks kill about 20 per year. Snakes kill 100,000 or 150,000, said Clevers.

Im a cancer researcher essentially and I am appalled by the difference in investment in cancer research and this research.

One challenge to making synthetic antivenom is the sheer complexity of how a snake disables its prey. Its venom contains several different components that have different effects.

Researchers in India have sequenced the genome of the Indian Cobra, in an attempt to decode the venom.

Published in the journal Nature Genetics earlier this month, its the most complete snake genome assembled and contains the genetic recipe for the snake venom, establishing the link between the snakes toxins and the genes that encode them. Its not a straightforward cocktail the team identified 19 genes out of 139 toxin genes as the ones responsible for causing harm in humans.

Its the first time a very medically important snake has been mapped in such detail, said Somasekar Seshagiri, president of SciGenom Research Foundation, a nonprofit research center in India.

It creates the blueprint of the snake and helps us get the information from the venom glands. Next, his team will map the genomes of the saw-scaled viper, the common krait and the Russells viper the rest of Indias big four. This could help make antivenom from the glands as it will be easier to identify the right proteins.

In tandem, both breakthroughs will also make it easier to discover whether some of the potent molecules contained in snake venom are themselves worth prospecting as drugs allowing snakes to make their mark on human health in a different way to how nature intended by saving lives.

Snake venom has been used to make drugs that treat hypertension (abnormally high blood pressure) and heart conditions such as angina.

As well as being scary, venom is amazingly useful, Seshagari said.

The rest is here:
Snake venom can now be made in a lab and that could save many lives - KTVZ

Stem Cell Therapy Market Predicted to Accelerate the Growth by 2017-2025 – Jewish Life News

By adminJanuary 29, 2020Stem Cell Doctors

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the MarketCLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Reportfor more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the rest here:
Stem Cell Therapy Market Predicted to Accelerate the Growth by 2017-2025 - Jewish Life News

Colleagues are registering as donors and raising funds to help Trowbridge firefighter Guy Tadman and the charities supporting him – Wiltshire Times

By adminJanuary 29, 2020Stem Cell Doctors

A Trowbridge firefighter is hoping his battle against leukaemia will lead to other cancer sufferers receiving life-saving treatment.

Watch Manager Guy Tadman was diagnosed with acute myeloid leukaemia at the end of November and has spent most of the last two months in the Royal United Hospital in Bath.

He has just finished his second round of chemotherapy and is now awaiting a decision by his doctors about the next steps in his treatment. However, it seems most likely he will need a stem cell transplant, possibly via a partial match from a family member.

Guy said: Finding a good stem cell match is really difficult, so getting more people registered as potential donors improves the odds for everyone in the situation Im in.

"Im incredibly lucky to have so many friends and colleagues who want to help, and it would be amazing if one of them proved to be the golden ticket for someone with cancer.

The Fire Brigades Union is leading the push for donors, and dozens of Mr Tadmans colleagues from Trowbridge fire station and elsewhere in Dorset & Wiltshire Fire and Rescue Service have already registered to become donors with the charity DKMS at http://www.dkms.org.uk.

Kate Scott, from the FBU, said: Guy is a good friend to so many people in our service but also in the wider fire family.

"Everyone wants to step up and do something, and hopefully one of the new donors will be a match for him or someone else. "Were also encouraging people to contribute financially, as every new donor swab kit costs the charity 40.DWFRS road safety manager Christine Sharma has already raised 1,930 for the Bloodwise charity by going #DryforGuy in a sponsored dry January - 1,114 of this came from Pewsey fire station, who held a car wash on January 4, supported by colleagues from Marlborough.

Fundraising events, including car washes, a ladder climb and an equipment carry challenge, are being planned across the service in support of the charities helping Guy and his family.

Someone You Should Know: The Relentless Pledge – KSFY

By adminJanuary 29, 2020Stem Cell Clinic

SIOUX FALLS, S.D. (Dakota News Now) - A Mitchell boy is defying one of the darkest times in his family's life, his dad's battle with cancer. He's turning it into a message of inspiration for others.

On that exact day maybe three hours later, that's when I started going door to door.

Floyd Korzan is a motivated kid. That's easy to see. It's also evident that he's caring and loves his dad very much.

"I remember some nights, they'd literally bring over a bed and I'd just sleep with him there.

His dad Matt spent a lot of time at the Mayo Clinic in Rochester, Minnesota battling leukemia from 2012 to 2017. It came back twice.

"The doctors at the Mayo Clinic told our family that the only thing more deadly than leukemia is relapsed leukemia, said Matt.

But Matt was relentless in his fight, a keyword in their family to this day.

"I'm a high-energy guy, this was crushing and devastating, said Matt. I'd never been sick a day in my life before this happened, it was crazy. But, my mindset is you got to be relentless. That's what I told Floyd. You got to fight, you got to get up, and you got to gut it out, you've got to be relentless.

Now that Matt has made it more than two years cancer-free thanks to a stem cell transplant they're doing something special.

But the impact it's had already, they did not expect.

Less than a month ago, Floyd, who's just 13 years old, started a nonprofit with his parents' help.

Its centered on that word, relentless.

"After I saw what struggle me, my dad and the rest of my family went through, I thought that that would've been a great motivator for some people to try to achieve their goals and overcome obstacles, said Floyd.

People can go online and take the relentless pledge, purchase a wristband, or nominate someone in their community to receive one for free whether that's a cancer patient or local heroes like police and firefighters.

"They have to risk their lives almost every day just to try to help people and I feel like that takes some relentlessness, said Floyd.

The Korzans have a website and social media pages for their relentless pledge. Thanks to the reach of their Facebook, it's already become a global movement.

"Floyd has had pledges and we've shipped these relentless wristbands to folks in 36 different states and three continents, these are people we've never heard of, we've received emails that would make you tear up, I'm really proud of it, said Matt.

Their goal is big.

"The goal is to get our relentless wristbands to every single cancer patient in America, said Matt.

But then again, they have a plan.

"To be relentless.

See the original post:
Someone You Should Know: The Relentless Pledge - KSFY

Cedars-Sinai Study Indicates That Parkinson’s Disease May Start Before Birth – Equities.com

By adminJanuary 29, 2020Stem Cell Clinic

Image: Nur Yucer, PhD, a project scientist, and Clive Svendsen, PhD, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute and Professor of Biomedical Sciences and Medicine at Cedars-Sinai. Photo by Cedars-Sinai.

Parkinson's disease is a neurodegenerative disorder that affects predominately dopamine-producing neurons in the brain. Nearly one million will be living with Parkinson's disease in the US this year, according to the Parkinson's Foundation. This is more than the number of people diagnosed with multiple sclerosis, muscular dystrophy and Lou Gehrig's diseasecombined.

About 60,000 Americans are diagnosed with Parkinson's disease each year, and more than 10 million people worldwide are living with it. Incidence of Parkinsons disease increases with age, but an estimated 10 percent of people with Parkinson's disease are diagnosed before age 50. This is called young-onset Parkinson's.

Researchers at Cedars-Sinai, led by Clive Svendsen, PhD, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute and Professor of Biomedical Sciences and Medicine at Cedars-Sinai, reported in a study published in Nature Medicine that they found that patients who develop young-onset Parkinsons disease may have been born with dysfunctional brain cells that go undetected for decades.

The research team generated special stem cells, known as induced pluripotent stem cells (iPSCs), from cells of patients suffering from young-onset Parkinsons disease. These iPSCswhich can produce any cell type of the human body, all genetically identical to the patients own cellswere used to produce dopamine neurons from each patient to analyze their functions.

Two key abnormalities were observed in these neurons:

- Dr. Clive Svendsen

After testing a number of drugs on the abnormal dopamine neurons, the researchers discovered that a drug called PEP005 (ingenol mebutate) reduced the elevated levels of alpha-synuclein in both the dopamine neurons in the dish and in laboratory mice. A gel formulation of PEP005 is marketed by LEO Pharma as Picato and is FDA-approved for the treatment of actinic keratosis, a scaly skin patch that develops from years of exposure to the sun. According to the Mayo Clinic, a small percentage of actinic keratosis lesions can eventually become skin cancer.

Michele Tagliati, PhD, Director of the Movement Disorders Program and Vice Chair and Professor in the Department of Neurology at Cedars-Sinai, said the research team next will study how PEP005 might be delivered to the brain and whether or not the abnormalities found in young-onset Parkinson's patients also exist in other forms of Parkinsons.

- Dr. Michele Tagliati.

Edward Kim is Managing Editor of Equities.com.

_____

Sources: Equities News, Cedars-Sinai

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Stem Cell and Primary Cell Culture Medium Market: Size, Share, Analysis, Region – News by aeresearch

By adminJanuary 29, 2020Stem Cell Clinic

Latest Market Research Report on Stem Cell and Primary Cell Culture Medium Market size | Industry Segment by Applications (Biopharmaceutical Manufacturing, Tissue Engineering & Regenerative Medicine, Gene Therapy and Other), by Type (Liquid Media and Powder Media), Regional Outlook, Market Demand, Latest Trends, Infrared Temperature Measurement Instruments Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025. Analyzes current market size and upcoming 5 years growth of this industry.

A basic outline of the competitive landscape:

This research report delivers a collective study on the Stem Cell and Primary Cell Culture Medium Industry, that also contains an intricate valuation of this business vertical. Also, segments of the Stem Cell and Primary Cell Culture Medium market have been clearly explained in this report, in addition to a basic overview of this market with respect to its present-day status as well as market size, in terms of returns and volume parameters.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/62644

A crisp outline of the market segmentation:

The report is a pervasive account of the important insights regarding the regional spectrum of this industry as well as the companies that have effectively established their standing in the Stem Cell and Primary Cell Culture Medium market.

How far does the scope of the Stem Cell and Primary Cell Culture Medium market traverse?

A complete outline of the regional spectrum:

Key Questions Answered in this Report

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/62644

Read the rest here:
Stem Cell and Primary Cell Culture Medium Market: Size, Share, Analysis, Region - News by aeresearch

Global Gene Therapy Market is Growing to Reach 6892 Million By 2027 – Market Research News 24

By adminJanuary 29, 2020Somatic Stem Cells

Facts and Factors Market Researchhas published a new report titled Gene Therapy Market By Type (Germ Line Gene Therapy and Somatic Gene Therapy), By Vector Type (Viral Vectors, Non-Viral Vectors, and Human Artificial Chromosome), and By Therapy Area (Cancer, Neurological Diseases, Infectious Diseases, Genetic Disorders, Rheumatoid Arthritis, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027.

According to the report, the globalgene therapy market was valued at approximately USD 919 million in 2018 and is expected to reach a value of around USD 6,892 million by 2027, at a CAGR of around 25.1% between 2019 and 2027.

Gene therapy is the kind of experimental method that makes use of genes for treating or preventing disease by inserting foreign genetic material like DNA or RNA into the persons cells. Scientists are studying gene therapy for treating various kinds of immuno-deficiencies, Parkinsons disease, HIV, and cancer by using myriad approaches. Today, many of the approaches to gene therapy are undergoing most intensive & rigorously testing. This includes replacing the mutated gene causing disease with the healthy gene copy. Another approach includes knocking out or inactivating a mutated gene operating improperly. Yet another approach includes a new gene into the body to combat the disease.

Request Free Sample Copy of Research Report @ https://www.fnfresearch.com/sample/gene-therapy-market-by-type-germ-line-gene

(The sample of this report is readily available on request. The free sample report on the Wheelchair Accessible Vehicle Converters market consists of data regarding the competitive terrain as well as analysis of the competitive scope of this industry.)

New product approval & commercialization to drive the market trends

Between the periods from 2012 to 2018, nearly five single-use gene treatments received approval from the U.S. FDA for treating a rare form of genetic disorders. Moreover, gene treatments that have received approval are being tested by pharmaceutical firms in the market. Apart from this, current approvals of gene therapy products across the U.S., as well as European countries for treating a plethora of life-threatening diseases, are anticipated to steer the growth of gene therapy industry over the forecast timeline. Moreover, gene therapy can also be used for treating neurodegenerative disorders like Alzheimer, amyotrophic lateral sclerosis, and spinal muscular atrophy.

Furthermore, many of the reputed pharma firms like Bristol-Myers Squibb, BioMarin, and Pfizer are investing massively into the research activities pertaining to gene therapy. Apart from this, a rise in the occurrence of cancer is prompting the demand to treat the disease. Gene therapy is one of the key treatment kinds that will propel the market growth over the forecast period. However, inadequate reimbursement policies pertaining to the one-time gene treatments will downgrade market expansion.

Inquire more about this report before purchase @ https://www.fnfresearch.com/inquiry/gene-therapy-market-by-type-germ-line-gene

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

In addition to this, conducting of randomized controlled trials can pose a threat to the expansion of the gene therapy industry as a result of the gene therapy features & projected patient population. Nevertheless, the ability of the gene therapy to eliminate the number of ailments with faulty or missing genes like hemophilia A will promote the market growth over the forecast period and thereby nullify the negative impact of hindrances on the business growth.

Somatic gene therapy to dominate the type segment

The growth of the segment over the forecast timeline is credited to the ability to treat the targeted cells in the patient population. The treatment is not passed to future generations and is restricted to only the patient who receives the somatic gene therapy. Moreover, it is used for treating a huge number of disorders like cystic fibrosis, cancer, and muscular dystrophy.

Cancer to lead the therapy area segment over the forecast period

The segmental expansion is attributed to a large number of pipeline drugs registered over the past few years along with increasing occurrence of cancer as a result of genetic changes.

North America to dominate the overall regional market share during the forecast timespan

North American market, which accrued revenue of USD 380 million in 2018, is set to contribute majorly towards the overall market revenue by 2027. The regional market surge is credited to robust healthcare amenities, high per capita healthcare spending, and improvement in the reimbursement policies.

Request customized copy of report @ https://www.fnfresearch.com/customization/gene-therapy-market-by-type-germ-line-gene

(We customize your report according to your research need. Ask our sales team for report customization)

The key players included in this market are Advanced Cell & Gene Therapy, Audentes Therapeutics, Benitec Biopharma, Biogen, Blubird Bio, Inc., Bristol-Myers Squibb Company, CHIESI Farmaceutici SPA, Eurofins Scientific, Geneta Science, Genzyme Corporation, Gilead, GlaxoSmithKline PLC, Human Stem Cells institute, Novartis AG, Orchard Therapeutics, Pfizer Inc., Sangamo therapeutics, Spark therapeutics, and Voyager Therapeutics.

This report segments the gene therapy market as follows:

Global Gene Therapy Market: By Type Segment Analysis

Global Gene Therapy Market: By Vector Type Segment Analysis

Global Gene Therapy Market: By Therapy Area Segment Analysis

Global Gene Therapy Market: Regional Segment Analysis

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,8 Century Avenue, Shanghai,Postal 200120, ChinaTel: +86 21 80360450

Email:sales@fnfresearch.com

Web:https://www.fnfresearch.com

Sorry! The Author has not filled his profile.

See the article here:
Global Gene Therapy Market is Growing to Reach 6892 Million By 2027 - Market Research News 24

Lab-grown heart cells implanted into human patient for the first time – New Atlas

By adminJanuary 29, 2020Stem Cell Medicine

In what is a world-first and potentially the dawn of a new medical technology to treat damaged hearts, scientists in Japan have succeeded in transplanting lab-grown heart cells into a human patient for the first time ever. The procedure is part of a cutting-edge clinical trial hoped to open up new avenues in regenerative medicine, with the treatment to be given to a further nine patients over the coming years.

The clinical trial harnesses the incredible potential of induced pluripotent stem cells (IPSCs), a Nobel Prize-winning technology developed at Kyoto University in 2006. These are created by first harvesting cells from donor tissues and returning them to their immature state by exposing them to a virus. From there, they can develop into essentially any cell type in the body.

Professor Yoshiki Sawa is a cardiac surgeon at Osaka University in Japan, who has been developing a technique to turn IPSCs into sheets of 100 million heart muscle cells, which can be grafted onto the heart to promote regeneration of damaged muscles. This was first tested on pigs and was shown to improve organ function, which led Japans health ministry to conditionally approve a research plan involving human subjects.

The first transplantation of these cells is a huge milestone for the researchers, with the operation taking place earlier this month and the patient now recovering in the general ward of the hospital. The sheets are biodegradable, and once implanted on the surface of the heart are designed to release growth factors that encourage new formation of healthy vessels and boost cardiac function.

The team will continue to monitor the first patient over the coming year, and over the next three years aims to carry out the procedure on a total of 10 patients suffering from ischemic cardiomyopathy, a condition caused by a heart attack or coronary disease that has left the muscles severely weakened.

I hope that [the transplant] will become a medical technology that will save as many people as possible, as Ive seen many lives that I couldnt save, Sawa said at a news conference on Tuesday, according to The Japan Times.

Source: The Japan Times